Your browser doesn't support javascript.
loading
Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis: Tumor Biology Cuts the Deal.
Eshmuminov, Dilmurodjon; Studer, Debora J; Lopez Lopez, Victor; Schneider, Marcel A; Lerut, Jan; Lo, Mary; Sher, Linda; Musholt, Thomas J; Lozan, Oana; Bouzakri, Nabila; Sposito, Carlo; Miceli, Rosalba; Barat, Shoma; Morris, David; Oehler, Helga; Schreckenbach, Teresa; Husen, Peri; Rosen, Charles B; Gores, Gregory J; Masui, Toshihiko; Cheung, Tan-To; Kim-Fuchs, Corina; Perren, Aurel; Dutkowski, Philipp; Petrowsky, Henrik; Thiis-Evensen, Espen; Line, Pål-Dag; Grat, Michal; Partelli, Stefano; Falconi, Massimo; Tanno, Lulu; Robles-Campos, Ricardo; Mazzaferro, Vincenzo; Clavien, Pierre-Alain; Lehmann, Kuno.
Afiliação
  • Eshmuminov D; Department of Surgery & Transplantation, University Hospital Zurich, Zurich, Switzerland.
  • Studer DJ; Department of Surgery & Transplantation, University Hospital Zurich, Zurich, Switzerland.
  • Lopez Lopez V; University of Zurich, Zurich, Switzerland.
  • Schneider MA; Clinic and University Virgen de la Arrixaca Hospital, IMIB-Arrixaca, Murcia, Spain.
  • Lerut J; Department of Surgery & Transplantation, University Hospital Zurich, Zurich, Switzerland.
  • Lo M; Institute for Experimental and Clinical Research (IREC), UCLouvain, Brussels, Belgium, Université Catholique Louvain (UCL), Brussels, Belgium.
  • Sher L; Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA.
  • Musholt TJ; Department of Surgery, University of Southern California, Keck School of Medicine, Los Angeles, CA.
  • Lozan O; Clinic of General, Visceral- and Transplantation Surgery, University Medical Center Mainz, Mainz, Germany.
  • Bouzakri N; Clinic of General, Visceral- and Transplantation Surgery, University Medical Center Mainz, Mainz, Germany.
  • Sposito C; Clinic of General, Visceral- and Transplantation Surgery, University Medical Center Mainz, Mainz, Germany.
  • Miceli R; Università degli Studi di Milano, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.
  • Barat S; Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS, Instituto Nazionale dei Tumori, Milan, Italy.
  • Morris D; South East Sydney Local Health District, Sydney, NSW, Australia.
  • Oehler H; South East Sydney Local Health District, Sydney, NSW, Australia.
  • Schreckenbach T; Department of General, Visceral, Transplantation and Thoracic Surgery, Goethe University Frankfurt, Frankfurt University Hospital, Frankfurt/Main, Germany.
  • Husen P; Department of General, Visceral, Transplantation and Thoracic Surgery, Goethe University Frankfurt, Frankfurt University Hospital, Frankfurt/Main, Germany.
  • Rosen CB; Division of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
  • Gores GJ; Division of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, MN.
  • Masui T; Mayo Clinic College of Medicine, Rochester, MN.
  • Cheung TT; Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Kim-Fuchs C; University of Hong Kong Queen Mary Hospital, Hong Kong, China.
  • Perren A; Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Dutkowski P; Inselspital Bern, Institute of Pathology, Bern, Switzerland.
  • Petrowsky H; Department of Surgery & Transplantation, University Hospital Zurich, Zurich, Switzerland.
  • Thiis-Evensen E; Department of Surgery & Transplantation, University Hospital Zurich, Zurich, Switzerland.
  • Line PD; Oslo University Hospital, Oslo, Norway.
  • Grat M; Oslo University Hospital, Oslo, Norway.
  • Partelli S; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Falconi M; Department of General, Transplant and Liver Surgery, Medical University of Warsaw, Warsaw, Poland.
  • Tanno L; Pancreas Translational & Clinical Research Center, San Raffaele Hospital IRCCS, Vita-Salute University, Milan, Italy.
  • Robles-Campos R; Pancreas Translational & Clinical Research Center, San Raffaele Hospital IRCCS, Vita-Salute University, Milan, Italy.
  • Mazzaferro V; University Hospital Southampton, ENETS Center of Excellence, Southampton, UK.
  • Clavien PA; Clinic and University Virgen de la Arrixaca Hospital, IMIB-Arrixaca, Murcia, Spain.
  • Lehmann K; Università degli Studi di Milano, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.
Ann Surg ; 277(5): e1063-e1071, 2023 05 01.
Article em En | MEDLINE | ID: mdl-35975918
ABSTRACT

BACKGROUND:

In patients with neuroendocrine liver metastasis (NELM), liver transplantation (LT) is an alternative to liver resection (LR), although the choice of therapy remains controversial. In this multicenter study, we aim to provide novel insight in this dispute.

METHODS:

Following a systematic literature search, 15 large international centers were contacted to provide comprehensive data on their patients after LR or LT for NELM. Survival analyses were performed with the Kaplan-Meier method, while multivariable Cox regression served to identify factors influencing survival after either transplantation or resection. Inverse probability weighting and propensity score matching was used for analyses with balanced and equalized baseline characteristics.

RESULTS:

Overall, 455 patients were analyzed, including 230 after LR and 225 after LT, with a median follow-up of 97 months [95% confidence interval (CI) 85-110 months]. Multivariable analysis revealed G3 grading as a negative prognostic factor for LR [hazard ratio (HR)=2.22, 95% CI 1.04-4.77, P =0.040], while G2 grading (HR=2.52, 95% CI 1.15-5.52, P =0.021) and LT outside Milan criteria (HR=2.40, 95% CI 1.16-4.92, P =0.018) were negative prognostic factors in transplanted patients. Inverse probability-weighted multivariate analyses revealed a distinct survival benefit after LT. Matched patients presented a median overall survival (OS) of 197 months (95% CI 143-not reached) and a 73% 5-year OS after LT, and 119 months (95% CI 74-133 months) and a 52.8% 5-year OS after LR (HR=0.59, 95% CI 0.3-0.9, P =0.022). However, the survival benefit after LT was lost if patients were transplanted outside Milan criteria.

CONCLUSIONS:

This multicentric study in patients with NELM demonstrates a survival benefit of LT over LR. This benefit depends on adherence to selection criteria, in particular low-grade tumor biology and Milan criteria, and must be balanced against potential risks of LT.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Ann Surg Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Fígado / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Revista: Ann Surg Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Suíça